Leonie Klimpke
Finanzdirektor/CFO bei Cavalry Ventures Management GmbH
Profil
Leonie Klimpke is currently the Head of Finance at Cavalry Ventures Management GmbH since 2022.
Previously, she worked as a Finance Manager at Eternygen GmbH from 2016 to 2020.
Ms. Klimpke completed her undergraduate degree at Vrije Universiteit Amsterdam in 2010 and her graduate degree at École des Hautes Études Commerciales de Paris in 2014.
Aktive Positionen von Leonie Klimpke
| Unternehmen | Position | Beginn |
|---|---|---|
Cavalry Ventures Management GmbH
 Cavalry Ventures Management GmbH Investment ManagersFinance Cavalry Ventures Management GmbH (Cavalry) is a venture capital firm founded in 2015 by Rouven Dresselhaus. The firm is headquartered in Berlin, Germany. | Finanzdirektor/CFO | 01.02.2020 |
Ehemalige bekannte Positionen von Leonie Klimpke
| Unternehmen | Position | Ende |
|---|---|---|
Eternygen GmbH
 Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Corporate Officer/Principal | 28.02.2020 |
Ausbildung von Leonie Klimpke
| École des Hautes Études Commerciales de Paris | Graduate Degree |
| Vrije Universiteit Amsterdam | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Cavalry Ventures Management GmbH
Cavalry Ventures Management GmbH Investment ManagersFinance Cavalry Ventures Management GmbH (Cavalry) is a venture capital firm founded in 2015 by Rouven Dresselhaus. The firm is headquartered in Berlin, Germany. | Finance |
Eternygen GmbH
Eternygen GmbH Pharmaceuticals: MajorHealth Technology Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany. | Health Technology |
